CA2381095A1 - Method for treating insulin resistance through hepatic nitric oxide - Google Patents

Method for treating insulin resistance through hepatic nitric oxide Download PDF

Info

Publication number
CA2381095A1
CA2381095A1 CA002381095A CA2381095A CA2381095A1 CA 2381095 A1 CA2381095 A1 CA 2381095A1 CA 002381095 A CA002381095 A CA 002381095A CA 2381095 A CA2381095 A CA 2381095A CA 2381095 A1 CA2381095 A1 CA 2381095A1
Authority
CA
Canada
Prior art keywords
compound
nitric oxide
liver
pharmaceutical composition
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002381095A
Other languages
French (fr)
Other versions
CA2381095C (en
Inventor
Wilfred Wayne Lautt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scimar Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381095A1 publication Critical patent/CA2381095A1/en
Application granted granted Critical
Publication of CA2381095C publication Critical patent/CA2381095C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is provided a method of increasing insulin sensitivity by administerin g an effective amount of a compound which stimulates nitric oxide production i n the liver. Also provided is a pharmaceutical composition having an effective amount of a compound which stimulates nitric oxide production in the liver a nd a pharmaceutically acceptable carrier.

Claims (8)

1. A method of increasing insulin sensitivity by:
administering an effective amount of a compound which stimulates nitric oxide production in the liver.
2. The method according to claim 1, wherein said administering step further includes orally administering the compound.
3. The method according to claim 1, wherein said administering step further includes injecting the compound.
4. The method according to claim 1, wherein said administering step further includes delivering the compound through a pump system directly into the portal vein.
5. A pharmaceutical composition comprising an effective amount of a compound which stimulates nitric oxide production in the liver and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition according to claim 5, wherein said compound is a nitric oxide agonist.
7. The pharmaceutical composition according to claim 5, wherein said compound is a nitric oxide donor.
8. The use of a compound which stimulates nitric oxide production in the liver and a pharmaceutically acceptable carrier.
CA2381095A 1998-10-06 1999-10-05 Method for treating insulin resistance through hepatic nitric oxide Expired - Lifetime CA2381095C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10317098P 1998-10-06 1998-10-06
US60/103,170 1998-10-06
PCT/US1999/023098 WO2000019992A1 (en) 1998-10-06 1999-10-05 Method for treating insulin resistance through hepatic nitric oxide

Publications (2)

Publication Number Publication Date
CA2381095A1 true CA2381095A1 (en) 2000-04-13
CA2381095C CA2381095C (en) 2012-08-14

Family

ID=22293754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2381095A Expired - Lifetime CA2381095C (en) 1998-10-06 1999-10-05 Method for treating insulin resistance through hepatic nitric oxide

Country Status (3)

Country Link
EP (1) EP1126831A4 (en)
CA (1) CA2381095C (en)
WO (1) WO2000019992A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471903B1 (en) * 2002-01-25 2019-11-20 SciMar Ltd. Use of glutathione synthesis stimulating compounds in reducing insulin resistance
CN1960735B (en) 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 The application of drug regimen in treatment insulin resistance
EP2788078B1 (en) 2011-12-09 2020-09-02 Metavention, Inc. Therapeutic neuromodulation of the hepatic system
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
US20160128767A1 (en) * 2013-06-05 2016-05-12 Metavention, Inc. Modulation of targeted nerve fibers
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods
CN110446501A (en) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 The dosage form of tissue kallikrein 1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
GB9510037D0 (en) * 1995-05-18 1995-07-12 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors

Also Published As

Publication number Publication date
WO2000019992A9 (en) 2000-09-21
EP1126831A4 (en) 2004-10-06
WO2000019992A1 (en) 2000-04-13
CA2381095C (en) 2012-08-14
EP1126831A1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
WO2005004895A3 (en) Compositions and methods for enhanced mucosal delivery of growth hormone
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
MY102378A (en) Transdermal delivery system.
AU3957400A (en) Dry, mouldable drug formulation
WO2003002103A3 (en) Hydrophobic dopamine agonists administered to the dermis
WO2001019428A3 (en) Multi-dose syringe driver
DE60021059D1 (en) HYDROGEL PARTICULAR FORMULATIONS
AU1534699A (en) Osmotic dosage form comprising first and second coats
CA2339218A1 (en) Methods and compositions for increasing insulin sensitivity
AU2084801A (en) Antiviral medication
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
CA2381095A1 (en) Method for treating insulin resistance through hepatic nitric oxide
ATE388687T1 (en) MEDICINAL ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING GUM
CA2340898A1 (en) Compositions and methods for treating intracellular infections
CA2356959A1 (en) Water-insoluble drug delivery system
ATE356637T1 (en) DRUGS CONTAINING SUPRAMOLECULAR COMPLEXES
CO4940454A1 (en) NEW METHOD OF TREATMENT
WO2001085139A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
AU2420001A (en) Methods and compositions for the treatment of pain
BG101884A (en) Salts of the clavulanic acid
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
NZ246748A (en) Migraine-preventing medicaments comprising a mast cell degranulation blocking agent (e.g. hydroxyzine, ketotifen, azatadine, azelastine, cyproheptadine, oxatomide, terfenadine, etc)
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
JPS55122721A (en) Antidiabetic agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20191007